Eledon Pharmaceuticals (ELDN) Expected to Announce Earnings on Wednesday

Key Points

• Eledon will report Q1 2026 results before the market opens on Wednesday, May 13, with analysts forecasting earnings of ($0.22) per share and an earnings call scheduled for Tuesday, May 12 at 4:00 PM ET.
• In its last report on March 19 the company posted EPS of ($0.10) (beating estimates), and the stock recently opened at $3.78 with a market cap of about $286.7 million and a 12‑month range of $1.35–$4.60.
• Wall Street sentiment is mixed: MarketBeat shows a consensus Hold with a $9.67 price target (3 Buys, 1 Hold, 1 Sell) while Weiss Ratings reiterated a "sell (d-)," and institutions now own roughly 56.8% of shares after several recent stake changes.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.22) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its earnings results on Thursday, March 19th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.10.

Eledon Pharmaceuticals Stock Performance

NASDAQ ELDN opened at $3.78 on Wednesday. The business's 50 day moving average is $3.06 and its two-hundred day moving average is $2.48. Eledon Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $4.60. The stock has a market capitalization of $286.72 million, a price-to-earnings ratio of -7.27 and a beta of 0.94.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Eledon Pharmaceuticals in a research report on Friday, March 27th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $9.67.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several institutional investors have recently modified their holdings of ELDN. BNP Paribas Financial Markets boosted its stake in shares of Eledon Pharmaceuticals by 143.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company's stock worth $31,000 after acquiring an additional 7,166 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $36,000. Virtu Financial LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $39,000. Cetera Investment Advisers boosted its stake in shares of Eledon Pharmaceuticals by 72.9% during the 4th quarter. Cetera Investment Advisers now owns 26,584 shares of the company's stock worth $40,000 after acquiring an additional 11,207 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 56.77% of the company's stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc NASDAQ: ELDN is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.